Hard to Treat Diseases, Inc.

Hard to Treat Diseases, Inc.

November 16, 2010 16:02 ET

Hard to Treat Diseases Inc. (PINK SHEETS:HTDS) Slavica Bio Chem Research Group Compete for the "Best Technological Innovation 2010" Award

BELGRADE, SERBIA--(Marketwire - Nov. 16, 2010) - Hard to Treat Diseases (PINK SHEETS:HTDS) www.htdsmedical.com and Slavica Bio Chem operating subsidiary www.slavicabiochem.com are delighted to report that IBISS research group after 8 months and 5 levels of competitions passed to the semi-final level of more than 250 competitors for the annual Award "Best technological innovation in Serbia in the year 2010" announced by Serbian Ministry of Science and Technological Development.

Prof. Dr. Mirjana Stojiljkovic, a Medical Advisor of HTDS, and the leader of the team said, "We are proud that, like last year, we are again among the best realized innovation ideas in Serbia, and our innovation and the business plan are well accepted. Namely, in the contest for the Best Technological Innovation in Serbia in the year 2009, Ministry of Science and Technological Development of Republic of Serbia awarded our team the second place of all scientific projects (and the first place for biological science) competed for this prestigious award, for the establishment of novel therapeutic approach in reducing and delaying of glial scar formation, a major factor in the failure of post-injury neurological recovery after the brain and spinal cord injury. For this purpose we used RIBAVIRIN, a substance that is in human practice as an antiviral drug. Importantly, beneficial effect of D-RIBAVIRIN was retained even 30 days after the cessation of drug administration. D-RIBAVIRIN treatment could also improve survival of transplants and new connections restitution between transplanted and host tissue. This is particularly interesting for embryonic, genetically modified tissue, and stem cells transplantations. Additionally, glial scar postponing via applying of RIBAVIRIN might considerably enhance recovery after brain ischemia or removing of brain and spinal cord tumors. Considering an enormous potential and benefit of RIBAVIRIN use in therapy of fore-mentioned patients, we expect a great breakthrough at the market and attention of pharmaceutical companies."

Prof. Dr. Mirjana Stojiljkovic added: "Our team wants to thank CEOs of MMMG who, on the behalf of HTDS, came to support us during this, for us, breaking point of contest."

At the company website http://www.htdsmedical.com/ very soon you can find the pictures from the contest. Additional details and information will be released promptly, via regular news release or Pink Sheets filing service.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this quarterly report constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contact Information